Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: A potential biomarker for detection of breast cancer in patients

Gheibi, A; Kazemi, M; Baradaran, A; Akbari, M; Salehi, M

Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: A potential biomarker for detection of breast cancer in patients

Authors

¹ Department of Biomedical Sciences, Division of Genetics, Isfahan, Iran

² Department of Pathology, Medical School, Isfahan, Iran

³ Department of Statistical science, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

⁴ Department of Biomedical Sciences, Division of Genetics, Isfahan; Medical Genetic Center of Genome,Isfahan, Iran

Abstract

Background: In recent years, DNA methylation as a main epigenetic modification in human cancer is found as a promising biomarker in early detection of breast cancer. Possible applications of numerous hypermethylated genes have been reported in diagnosis of breast cancer but there has been a little comprehensive study on the clinical usefulness of these genes in breast cancer. The aim of the present study was to investigate the promoter methylation status of 14-3-3 sigma gene with the goal of developing a diagnostic application in breast cancer.
Materials and Methods: Totally 40 cases of cancerous and noncancerous tissues were studied. DNA was extracted from tissue samples, and promoter methylation pattern was determined by using methylation-specific polymerase chain reaction.
Results: Methylation pattern of 14-3-3 sigma promoter significantly differed between control and malignant breast tissues ( P = 0.001), and there was no remarkable correlation between methylation and age ( P > 0.05).
Conclusion: The relationship of promoter methylation of 14-3-3 sigma with development of breast cancer found in this study and confirmed the results of previous reports suggests that we can provide the foundation for possible application of 14-3-3 sigma as a potential biomarker for early detection and monitoring disease status.

Keywords

References

1.	Brooks M. Breast cancer screening and biomarkers. Methods Mol Biol 2009;472:307-21. [PUBMED]
2.	Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide, Int J Cancer 2000. Version 1.0. Available from: http://www.dep.iarc.fr/globocan/globocan.html [Last accessed on 2012Feb 23].
3.	Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81. [PUBMED]
4.	Montazeri A, Ebrahimi M, Mehrdad N, Ansari M, Sajadian A. Delayed presentation in breast cancer: A study in Iranian women. BMC Womens Health 2003;3:4. [PUBMED]
5.	Nagel GC, Schmidt S, Strauss BM, Katenkamp D. Quality of life in breast cancer patients: A cluster analytic approach. Empirically derived subgroups of the EORTC-QLQ BR 23-a clinically oriented assessment. Breast Cancer Res Treat 2001;68:75-87. [PUBMED]
6.	Efficace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicenter study. J Clin Oncol 2004;22:3381-8. [PUBMED]
7.	Yang X, Yan L, Davidson NE. DNA methylation in breast cancer. Endocr Relat Cancer 2001;8:115-27. [PUBMED]
8.	Franklin TB, Mansuy IM. Epigenetic inheritance in mammals: Evidence for the impact of adverse environmental effects. Neurobiol Dis 2010;39:61-5. [PUBMED]
9.	Feinberg AP. Cancer epigenetics takes center stage. Proc Natl Acad Sci U S A 2001;98:392-4. [PUBMED]
10.	Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K, Herman JG. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001;10:687-92. [PUBMED]
11.	Barekati Z, Radpour R, Kohler C, Zhong XY. Specificity of methylation assays in cancer research: A guideline for designing primers and probes. Obstet Gynecol Int 2010;2010.pii: 870865.
12.	Widschwendter M, Jones PA.The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin Cancer Res 2002;8: 17-21. [PUBMED]
13.	Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66. [PUBMED]
14.	Tlsty TD, Crawford YG, Holst CR, Fordyce CA, Zhang J, McDermott K, et al. Genetic and epigenetic changes in mammary epithelial cells may mimic early events in carcinogenesis. J Mammary Gland Biol Neoplasia 2004;9:263-74. [PUBMED]
15.	Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001;357:1335-6. [PUBMED]
16.	Krassenstein R, Sauter E, Dulaimi E, Battagli C, Ehya H, Klein-Szanto A, et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004;10:28-32. [PUBMED]
17.	Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3 Sigma is required to prevent mitotic catastrophe after DNA damage. Nature 1999;401:616-20. [PUBMED]
18.	Pulukuri SM, Rao JS. CpG island promoter methylation and silencing of 14-3-3 sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2. Oncogene 2006;25:4559-72. [PUBMED]
19.	Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, et al. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc Natl Acad Sci U S A 2000;97:6049-54. [PUBMED]
20.	Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, et al. Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 2004;316:1156-62. [PUBMED]
21.	Mhawech P, Benz A, Cerato C, Greloz V, Assaly M, Desmond JC, et al. Downregulation of 14-3-3 sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 2005;18:340-8. [PUBMED]
22.	Lodygin D, Yazdi AS, Sander CA, Herzinger T, Hermeking H. Analysis of 14-3-3 sigma expression in hyperproliferative skin diseases reveals selective loss associated with CpG-methylation in basal cell carcinoma. Oncogene 2003;22:5519-24. [PUBMED]
23.	Osada H, Tatematsu Y, Yatabe Y, Nakagawa T, Konishi H, Harano T, et al. Frequent and histological type-specific inactivation of 14-3-3 sigma in human lung cancers. Oncogene 2002;21:2418-24. [PUBMED]
24.	Iwata N, Yamamoto H, Sasaki S, Itoh F, Suzuki H, Kikuchi T, et al. Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma. Oncogene 2000;19:5298-302. [PUBMED]
25.	Lodygin D, Hermeking H. The role of epigenetic inactivation of 14-3-3 sigma in human cancer. Cell Res 2005;15:237-46. [PUBMED]
26.	Korshunova Y, Maloney RK, Lakey N, Citek RW, Bacher B, Budiman A, et al. Massively parallel bisulphate pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. Genome Res 2008;18:19-29.
27.	Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007;81:280-7. [PUBMED]
28.	Zurita M, Lara PC, del Moral R, Torres B, Linares-Fernández JL, Arrabal SR, et al. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 2010;10:217.
29.	Luo J, Feng J, Lu J, Wang Y, Tang X, Xie F, et al. Aberrant methylation profile of 14-3-3 sigma and its reduced transcription/expression levels in Chinese sporadic female breast carcinogenesis. Med Oncol 2010;27:791-7. [PUBMED]
30.	Roma AA, Goldblum JR, Fazio V, Yang B. Expression of 14-3-3 sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma. Int J Clin Exp Pathol 2008;1:419-25. [PUBMED]

Advanced Biomedical Research